Results 11 to 20 of about 8,980 (210)
Treatment planning software for HIPEC [PDF]
, 2023 Peritoneal metastases (PM) predominantly originate from primary cancers such as colorectal, ovarian and gastric cancer. Survival rates decrease dramatically when metastases develop in the peritoneal cavity. The combination of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) offers a treatment option that can ...
Löke, D.R.
core +24 more sources
HIPEC for ovarian cancer [PDF]
, 2021 Eierstokkanker staat in de top 10 van kankerdiagnoses bij vrouwen wereldwijd. Ongeveer 70-80% van de patiënten met eierstokkanker, heeft deze ziekte in stadium III of IV, waarbij de ziekte is uitgezaaid naar het buikvlies of buiten de buikholte. De behandeling van eierstokkanker bestaat uit chirurgie, chemotherapie en doelgerichte onderhoudstherapie ...
Koole, S.N.
core +9 more sources
Swedish Experience with Peritonectomy and HIPEC. HIPEC in Peritoneal Carcinomatosis
Annals of Surgical Oncology, 2007 Peritonectomy with heated intraperitoneal chemotherapy (HIPEC) has shown a survival benefit in selected patients with peritoneal carcinomatosis. This prospective non-randomized study was designed to identify factors associated with postoperative morbidity and survival after peritonectomy HIPEC in patients with this condition.Data were prospectively ...
B L, van Leeuwen +3 more
openaire +3 more sources
Annals of Surgical OncologyThis manuscript reports the results of an international consensus on technologies of hyperthermic intraperitoneal perioperative chemotherapy (HIPEC) performed with the following goals: To provide recommendations for the technological parameters to perform HIPEC.
Kurt, Van der Speeten +6 more
openaire +3 more sources
Serum procalcitonin improves diagnosis of infectious complications after CRS/HIPEC
World Journal of Surgical Oncology, 2023 Background Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) improve the survival of selected patients with peritoneal metastasis. A major cause of treatment-related morbidity after CRS/HIPEC is infection and sepsis. HIPEC
Lilian Roth +6 more
doaj +2 more sources
Propensity score-matched evaluation of prophylactic hyperthermic intraperitoneal chemotherapy in geriatric patients with locally advanced colorectal cancer: safety and survival benefits [PDF]
BMC CancerAim The role of prophylactic hyperthermic intraperitoneal chemotherapy (HIPEC) in elderly patients with locally advanced colorectal cancer (LACRC) remains controversial. This study aimed to evaluate the perioperative safety and survival benefits of HIPEC
Min Yang +4 more
doaj +2 more sources
Development of a Nanocrystalline Paclitaxel Formulation for Hipec Treatment [PDF]
Pharmaceutical Research, 2012 To develop a nanocrystalline paclitaxel formulation with a high paclitaxel-to-stabilizer ratio which can be used for hyperthermic intraperitoneal chemotherapy (HIPEC).Paclitaxel (PTX) nanocrystals were prepared via wet milling using Pluronic F127(®) as stabilizer.
De Smet, Lieselotte +6 more
openaire +5 more sources
Hyperthermic intraperitoneal chemotherapy as consolidation treatment of advanced stage ovarian cancer [PDF]
Obstetrics & Gynecology Science, 2021 Objective To investigate the therapeutic efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) as consolidation treatment after completing first-line treatment in patients with advanced ovarian cancer.
Jieun Ko +8 more
doaj +1 more source
International Journal of Hyperthermia, 2023 Background The original meta-analysis of hyperthermic intraperitoneal chemotherapy (HIPEC) is already outdated, owing to the latest trial results. This study aimed to clarify the efficacy and adverse events of cytoreductive surgery with HIPEC compared to
Yu Xia +3 more
doaj +1 more source
Frontiers in Oncology, 2023 ObjectiveTo explore the clinical efficacy of lobaplatin-based prophylactic hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with T4 gastric cancer after surgery and to evaluate its impact on survival.Materials and methodsData on patients ...
Yuxin Zhong +5 more
doaj +1 more source